About: Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
Creator	Peghin, Maddalena Bassi, Flavio Bove, Tiziana Curcio, Francesco De Monte, Amato De Vita, Salvatore Fabris, Martina Mcgonagle, Dennis Orcid, ; Pecori, Davide Quartuccio, Luca Sonaglia, Arianna Tascini, Carlo
source	Elsevier; Medline; PMC
abstract	OBJECTIVE: Approximately 5% of patients with coronavirus disease 2019 (COVID-19) develop a life-threatening pneumonia that often occurs in the setting of increased inflammation or “cytokine storm”. Anti-cytokine treatments are being evaluated but optimal patient selection remains unclear, and the aim of our study is to address this point. METHODS: Between February 29 to April 6, 2020, 111 consecutive hospitalized patients with COVID-19 pneumonia were evaluated in a single centre retrospective study. Patients were divided in two groups: 42 severe cases (TOCI) with adverse prognostic features including raised CRP and IL-6 levels, who underwent anti-cytokine treatments, mostly tocilizumab, and 69 standard of care patients (SOC). RESULTS: In the TOCI group, all received anti-viral therapy and 40% also received glucocorticoids. In TOCI, 62% of cases were ventilated and there were 3 deaths (17.8 ± 10.6 days, mean follow up) with 7/26 cases remaining on ventilators, without improvement, and 17/26 developed bacterial superinfection. One fatality occurred in the 15 TOCI cases treated on noninvasive ventilation and 1 serious bacterial superinfection. Of the 69 cases in SOC, there was no fatalities and no bacterial complications. The TOCI group had higher baseline CRP and IL-6 elevations (p < 0.0001 for both) and higher neutrophils and lower lymphocyte levels (p = 0.04 and p = 0.001, respectively) with the TOCI ventilated patients having higher markers than non-ventilated TOCI patients. CONCLUSION: Higher inflammatory markers, more infections and worse outcomes characterized ventilated TOCI cases compared to ward based TOCI. Despite the confounding factors, this suggests that therapy time in anti-cytokine randomized trials will be key.
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1016/j.jcv.2020.104444
bibo:pmid	32425662
has license	no-cc
sha1sum (hex)	fa1f6da66c89794b6eb3720de5d1bf9c4dd3079e
schema:url	https://doi.org/10.1016/j.jcv.2020.104444
resource representing a document's title	Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
has PubMed Central identifier	PMC7227535
has PubMed identifier	32425662
schema:publication	J Clin Virol
resource representing a document's body	covid:fa1f6da66c89794b6eb3720de5d1bf9c4dd3079e#body_text
is schema:about of	covid:arg/fa1f6da66c89794b6eb3720de5d1bf9c4dd3079e named entity 'cytokine storm syndrome' named entity 'LDH' named entity 'standard of care' named entity 'ICU' named entity 'WBC' named entity 'tocilizumab' named entity 'CD4+' named entity 'LDH' named entity 'pneumonia' named entity 'Tocilizumab' named entity 'TOCI' named entity 'LDH' named entity 'IL-6' named entity 'COVID' named entity 'COVID' named entity 'anakinra' named entity 'TOCI' named entity 'inflammation' named entity 'neutrophil' named entity 'LDH' named entity 'D-dimer' named entity 'ICU' named entity 'Helsinki Declaration' named entity 'tocilizumab' named entity 'retrospective study' named entity 'iatrogenic infections' named entity 'written consent' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'obesity' named entity 'SPSS' named entity 'cytokine' named entity 'immunoassay' named entity 'nucleic acid sequencing' named entity 'prognosis' named entity 'hypercoagulable state' named entity 'Fisher exact test' named entity 'tocilizumab' named entity 'physiological range' named entity 'IL-6' named entity 'LDH' named entity 'prognosis' named entity 'intravenously' named entity 'Lymphocyte' named entity 'COVID-19' named entity 'NLR' named entity 'inflammation' named entity 'COVID' named entity 'tocilizumab' named entity 'open-label trial' named entity 'χ2 test' named entity 'CRP' named entity 'ischemic heart disease' named entity 'diabetes' named entity 'laboratory tests' named entity 'missing data' named entity 'standard deviation' named entity 'tocilizumab' named entity 'IL-6' named entity 'high levels' named entity 'critically ill patients' named entity 'cytokine storm' named entity 'monocyte' named entity 'antibodies' named entity 'serum' named entity 'ICU' named entity 'neutrophil' named entity 'TOCI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software